Eastbourne

Researchers are studying the clinical and health-related outcomes of treatments containing amivantamab for people with common EGFR-mutated advanced non-small cell lung cancer (NSCLC), which is the most common type of lung cancer. This type of cancer can spread to other parts of the body and occurs due to changes in genes such as the epidermal growth factor receptor (EGFR). The study focuses on real-world use of these treatments outside of controlled clinical trials. Participants will receive amivantamab-containing regimens as part of their standard care, decided by their doctors according to approved guidelines and local recommendations for supportive medications. The study observes patients starting these treatments for the first time and follows their clinical course as they receive care in usual medical settings. During the study, researchers will collect data for up to approximately 60 months to understand how long patients continue treatment and other health outcomes. Data collection includes monitoring treatment use, clinical responses, and safety in a real-world context. Participants or their representatives must provide consent for data verification, and the study tracks outcomes during routine clinical visits without altering standard treatment practices.

Researchers are investigating preventive treatments to reduce the occurrence, severity, and duration of taste changes (dysgeusia) related to talquetamab and ramantamig in patients with multiple myeloma. This Phase 2 open-label study aims to better understand the signs and symptoms of these oral events during a preventive treatment phase. Participants have multiple myeloma and have previously received specific prior therapies. The study involves several treatment options, including talquetamab and ramantamig, both given by subcutaneous injection, along with four different prophylaxis treatments (Prophylaxis A, B, C, and D) administered either orally or topically. These treatments are evaluated during the prophylaxis phase lasting up to 12 months. The goal is to assess how well these interventions prevent taste changes associated with talquetamab. Participants will be monitored for the presence and severity of taste changes through a standardized taste test called the Total Waterless Empirical Taste Test (WETT). Researchers will measure the percentage of participants experiencing dysgeusia, time to onset of severe taste changes, and the percentage reporting improvement or resolution at specific time points during the 12-month prophylaxis phase. Safety and adherence to lifestyle guidelines are also part of the participant evaluations throughout the study.

WAYFIND-R is a global registry focused on collecting high-quality real-world data from cancer patients diagnosed with solid tumors who have undergone next-generation sequencing (NGS) testing. The registry aims to support clinical and epidemiological research, generate evidence to better understand health outcomes and cancer care, and describe treatments and clinical courses for these patients. Participants must be adults diagnosed with any type of solid tumor at any disease stage and have had NGS testing within three months before enrollment. The study collects data without assigning specific treatments or interventions, instead tracking clinical characteristics and outcomes over time. During the study, researchers will gather information linking NGS results to treatments and patient outcomes, including overall survival for up to five years from enrollment. Participants provide informed consent, and data collected will help improve understanding of solid tumor cancers and their management in real-world settings.

Researchers are evaluating a phase III randomized clinical trial for patients with unilateral malignant pleural mesothelioma (MPM). The study aims to compare progression-free survival and overall survival between two approaches: proton beam therapy and standard surveillance. Patients will be stratified based on tumor histology, treatment center, tumor side, and time since diagnosis to assess these outcomes. Participants in the experimental group will receive proton beam therapy targeted at the hemithorax, delivering a total dose of 50Gy in 25 daily fractions over five weeks, with an additional boost to 60Gy for visible tumors. The control group will undergo standard care surveillance without immediate treatment, with immunotherapy or chemotherapy offered if disease progression occurs. Both groups will be followed for two years from randomization. During the study, patients will have regular follow-up visits at their local trial sites for assessments including safety, tolerability, quality of life questionnaires, and disease monitoring. The main outcomes measured are progression-free survival and overall survival up to two years. The study plans to recruit 148 patients across 20 UK centers, with additional interim analyses to evaluate treatment efficacy and safety throughout the trial period.

Researchers are evaluating a medicine called elranatamab for the treatment of multiple myeloma (MM), a type of cancer. This study focuses on people aged 18 or older who have MM that has returned or not responded to previous treatments, including prior use of an anti-CD38 antibody and lenalidomide. The goal is to compare elranatamab to other common combination therapies that include 2 to 3 different MM medicines. This is a Phase 3 study to learn about the safety and effectiveness of elranatamab compared to these other treatments. Participants will be randomly assigned to receive either elranatamab or a combination therapy selected by the study doctor. Elranatamab is given as a shot under the skin at the study clinic about once a week, which may later reduce in frequency. The combination therapy options include medicines taken by mouth and given either as shots under the skin or through a needle in the vein at the clinic. The combination medicines used may be elotuzumab, pomalidomide, dexamethasone, bortezomib, or carfilzomib, depending on the chosen treatment plan. Participants may continue their assigned treatment until their MM stops responding. During the study, participants will visit the clinic regularly for monitoring and evaluation. Researchers will track how well the treatments work by measuring progression-free survival and will watch for any side effects or safety concerns. Follow-up will continue after treatment ends through phone calls or visits. The study may last up to about 5 years to fully assess the outcomes of the treatments.

Researchers are studying patients with chronic lymphocytic leukaemia (CLL) who are treated with acalabrutinib in the United Kingdom. This observational research looks back at real-world clinical outcomes for patients who started acalabrutinib through the UK's Early Access Programme (EAP). The study aims to describe characteristics of these patients and estimate progression-free survival, overall survival, response rates, treatment patterns, and healthcare resource use. The study focuses on patients who began first-line treatment with acalabrutinib between April 1, 2020, and April 1, 2021. It collects clinical data from patients' medical records in accordance with local laws. This non-interventional study does not assign treatments but observes outcomes from the use of acalabrutinib as provided in routine care. Participants' medical records will be reviewed to assess progression-free survival at multiple time points up to five years, along with other outcomes such as overall survival and treatment responses. The study also evaluates healthcare resource use and post-progression treatments. By gathering this data, researchers aim to provide useful real-world evidence on acalabrutinib's use in the UK for patients with CLL over the course of their treatment.